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Abstract
Background: Anticitrullinated protein antibodies (ACPA) and citrullinated proteins play key roles in the
pathogenesis of rheumatoid arthritis (RA). Many candidate citrullinated antigens have been identified in joints, but
citrullinated proteins in sera are mostly uncertain in patients with RA. We explored the expression of citrullinated
proteins in joints and sera of experimental arthritis, and we further investigated their specific expression correlated
with the disease activity in patients with RA.
Methods: Citrullinated protein expression in tissues was examined by IHC in peptide glucose-6-phosphate
isomerase-induced arthritis (pGIA). Serum citrullinated proteins from pGIA were examined by Western blotting, and
the sequence was identified by MS. With the same methods, serum citrullinated proteins were analyzed in patients
with RA, primary Sjögren’s syndrome, systemic lupus erythematosus, and osteoarthritis as well as in healthy subjects,
by Western blotting and MS. In patients with RA, the relationship between the expression of the identified protein
(inter-alpha-trypsin inhibitor heavy chain 4 [ITIH4]) and clinical features was evaluated, and the levels of citrullinated
ITIH4 were compared before and after biological treatment. The antibody response against citrullinated ITIH4
peptide was measured by enzyme-linked immunosorbent assay.
Results: Citrullinated proteins were detected specifically in arthritic joints and sera from pGIA relative to controls.
In sera, a common band of citrullinated protein at 120 kDa was revealed, and it fluctuated in parallel with arthritis
score of pGIA by Western blotting. Interestingly, in 82% of RA patient sera, similar bands of citrullinated protein
were specifically detected. These proteins were identified as citrullinated ITIH4, and especially the R438 site was
commonly citrullinated between mice and humans. Citrullinated ITIH4 levels were associated with clinical
parameters such as C-reactive protein (CRP), rheumatoid factor, and Disease Activity Score in 28 joints as measured
by CRP in patients with RA. Its levels were decreased in correlation with the reduction of disease activity score after
effective treatment in patients with RA. Moreover, antibody response to citrullinated epitope in ITIH4 was
specifically observed in patients with RA.
Conclusions: Our results suggest that serum citrullinated ITIH4 was specifically increased in patients with RA and
could be a novel biomarker for assessing disease activity in patients with RA.
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Background
Rheumatoid arthritis (RA) is an autoimmune disease
characterized by the inflammation and destruction of
joints and surrounding tissues [1]. Most patients with
RA are positive for anticitrullinated protein antibodies
(ACPA), and these antibodies are highly specific for RA
diagnosis [2]. ACPA appear years before the onset of
clinical RA and are the predictive factor of joint radio-
graphic progression [2]. In the mouse model, it was re-
ported that ACPA appeared prior to the development of
clinical disease in collagen-induced arthritis, and adminis-
tration of anticitrullinated fibrinogen antibodies enhanced
arthritis [3]. Thus, ACPA is considered to be involved in
the pathogenesis of RA.
ACPA recognize various citrullinated proteins, such as
vimentin, α-enolase, fibrinogen, fibronectin, and glucose-
6-phosphate isomerase (GPI) [2, 4]. High levels of citrulli-
nated proteins have been found in RA joints [5, 6]. Also,
citrulline-specific T cells were increased in peripheral
blood of patients with RA and decreased by therapy [7].
In murine models, immunization of citrullinated fibrino-
gen induced arthritis in HLA-DRB1*0401-transgenic mice,
but unmodified fibrinogen did not [8]. However, we do
not know what citrullinated antigens specifically revealed
in joints and sera in arthritis.
GPI is a ubiquitous glycolytic enzyme and was identi-
fied as a pathogenic autoantigen in K/BxN arthritic mice
[9]. Immunization with recombinant human GPI could
induce arthritis in DBA/1 mice [10]. A major epitope
of GPI-specific CD4+ T cells in glucose-6-phosphate
isomerase-induced arthritis (GIA) was identified as
peptide 325–339 glucose-6-phosphate isomerase (pGPI),
and immunization with pGPI can also induce arthritis just
as GIA does in DBA/1 mice (peptide 325–339 glucose-6-
phosphate isomerase-induced arthritis [pGIA]) [11]. CD4+
T cells play a critical role in GIA [10, 12], and the effect of
biological agents in GIA is similar to RA [12, 13].
However, the involvement of ACPA and citrullinated
proteins have not investigated in this model.
In the present study, we explored the expression and
commonality of citrullinated proteins in pGIA and pa-
tients with RA, and we further investigated its correl-
ation with RA disease activity. We show the production
of ACPA, and we detected citrullinated proteins in arth-
ritic joints and sera in pGIA. Serum citrullinated protein
in pGIA was identified as citrullinated inter-alpha-
trypsin inhibitor heavy chain 4 (ITIH4). The expression
of ITIH4 was increased in inflamed synovium at day 14
in pGIA, suggesting the association with arthritis. In
addition, bands of the same size were also detected in
sera of patients with RA by Western blotting, which
were confirmed as citrullinated ITIH4 as well. The levels
of citrullinated ITIH4 were specifically increased in sera
of patients with RA and were clearly associated with RA
disease activity. Moreover, antibody response to citrulli-
nated epitope in ITIH4 was observed in patients with RA.
Citrullinated ITIH4 could be a novel specific biomarker
representing the disease activity of patients with RA.
Methods
Mice
Male DBA/1 mice were purchased from Charles River
Japan (Tokyo, Japan), and used at 6–10 weeks of age. All
mice were maintained under specific pathogen-free con-
ditions at the University of Tsukuba. All experimental
protocols were approved by the Institutional Animal
Care and Use Committee of the University of Tsukuba,
and all animal experiments were conducted in accord-
ance with institutional ethics guidelines. All surgeries
were performed under isoflurane anesthesia, and utmost
care was taken to minimize suffering.
Serum samples
Serum samples were collected from Japanese patients
with RA (n = 60, mean age 52.2 years, range 20–73
years, females 80%) diagnosed by rheumatologists ac-
cording to the 1987 American College of Rheumatology
(ACR) classification criteria [14] or the 2010 ACR/Euro-
pean League Against Rheumatism classification criteria
[15]. Serum samples of the disease control subjects were
collected from Japanese patients with primary Sjögren’s
syndrome (SS) (n = 27, mean age 58.8 years, range 26–80
years, females 96%), systemic lupus erythematosus (SLE)
(n = 15, mean age 33.9 years, range 16–55 years, females
80%), or osteoarthritis (OA) (n = 12, mean age 56.3 years,
range 37–80 years, females 67%). All the patients with SS
were diagnosed by rheumatologists according to the 1999
Japanese Ministry of Health criteria for diagnosis of SS
[16]. All the patients with SLE fulfilled the 1997 ACR clas-
sification criteria [17]. None of the patients with SS or
SLE had overlapping RA. Serum samples were collected
from healthy subjects (HS) (n = 30, mean age 49.0
years, range 34–65 years, females 80%). Serum samples
were also collected from 17 patients with RA before
and 24 weeks after treatment with biologic drugs
(infliximab, n = 9; abatacept, n = 8). All samples were
collected at the University of Tsukuba Hospital after in-
formed consent was obtained. This study was reviewed
and approved by the ethics committee of the University
of Tsukuba.
Peptide GPI-induced arthritis
DBA/1 mice were immunized with 25 μg of pGPI (Invi-
trogen/Thermo Fisher Scientific, Carlsbad, CA, USA) in
complete Freund’s adjuvant (CFA) (BD Biosciences, San
Jose, CA, USA). pGPI was emulsified with CFA at a 1:1
ratio (vol/vol), or PBS + CFA was prepared as a vehicle
control. For induction of arthritis, 150 μl of the emulsion
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was injected intradermally at the base of the tails of the
mice. Each mouse was also given an injection of 200 ng
of pertussis toxin (Sigma-Aldrich, St. Louis, MO, USA)
intraperitoneally on days 0 and 2 after immunization to
induce arthritis. Arthritis was assessed every other day
and evaluated using a scale of 0–3 for swelling and
redness of each paw. The clinical score was the sum of
the scores for four paws, as described previously [11].
Measurement of anti-CCP antibodies in pGIA
Sera were obtained on days 0–28 every week from mice
immunized with pGPI or control, and antibodies were
measured by enzyme-linked immunosorbent assay
(ELISA). Sera were diluted 1:25 in dilution buffer and
added to the 96-well plate (Immunoscan CCPlus test
kit; Euro Diagnostica, Malmö, Sweden) for 1 h at room
temperature. After a washing step, horseradish peroxid-
ase (HRP)-conjugated polyclonal rabbit antimouse im-
munoglobulin (Dako, Carpinteria, CA, USA) diluted 1:
1000 was added for 30 minutes at room temperature.
After another washing step, color was developed with
3,3′,5,5′-tetramethylbenzidine (TMB) microwell perox-
idase substrate (KPL/SeraCare, Milford, MA, USA).
The optical density (OD) was measured at 450 nm by
using a microplate reader.
A standard pool was obtained by mixing sera obtained
from several mice on day 28. The concentrations of anti-
bodies in this pool were considered 100 U/ml. A stand-
ard curve was obtained using serum dilutions, and the
Michaelis-Menten equation was used to convert OD
values into units, as described previously [18].
Measurement of anti-ITIH4 antibodies in patients with RA
Native peptide ITIH4428–447 and R438 citrullinated peptide
ITIH4428–447 were synthesized (serum, purity 95%) and
used in ELISA. Ninety-six-well plates (Nunc MaxiSorp;
Thermo Fisher Scientific) were coated with 10 μg/ml pep-
tides for 12 h at 4 °C. After washing and blocking steps,
sera from patients with RA (n = 60) and HS (n = 30) were
diluted 1:200 in 1% bovine serum albumin (BSA) in PBS,
then added for 2 h at room temperature. After a washing
step, HRP-conjugated goat antihuman immunoglobu-
lin G (IgG) (heavy and light chains [H + L]) (Abcam,
Cambridge, MA, USA) diluted 1:10,000 was added for
1 h at room temperature. After washing, color was
developed with TMB microwell peroxidase substrate
(KPL/SeraCare). The OD was measured at 450 nm by
using a microplate reader. The cutoff value was deter-
mined as the mean + 2 SD of HS.
Histopathological analysis
Ankle joint tissue samples were harvested at days 0 and
14 from mice immunized with pGPI or control. They
were fixed in neutralized 10% formalin, embedded in
paraffin, and sectioned. To detect citrullinated proteins,
we prepared modification buffer by mixing Reagent A
(20% H2SO4, 25% H3PO4, and 0.025% FeCl3) and Re-
agent B (1% diacetyl monoxime, 0.5% antipyrine, 1 M
acetic acid) at a 2:1 ratio (vol/vol). The sections were
covered with the modification buffer and incubated in a
light-proof container at 37 °C for 2.5 h to modify citrul-
line residues. Then, the sections were incubated over-
night at room temperature with rabbit anti-modified
citrulline (AMC) polyclonal antibodies diluted 1:3200 in
2% BSA in PBS to detect modified citrulline residues
[19]. The sections were also incubated with HRP-
conjugated goat antirabbit IgG (H + L) (Bio-Rad Labora-
tories, Hercules, CA, USA) for 30 minutes at room
temperature. The sections were also stained with 3,3′-di-
aminobenzidine (DAB) (Nichirei Biosciences, Tokyo,
Japan) and hematoxylin. To detect ITIH4 or macro-
phages, IHC analysis of the joint or liver (as a positive
control of ITIH4 staining) sections was performed as de-
scribed above, using rabbit antihuman ITIH4 antibodies
(Abcam) diluted 1:1000 and rat antimouse F4/80 anti-
bodies (BioLegend, San Diego, CA, USA) diluted 1:200 as
primary antibodies and using rabbit-specific IHC polymer
detection kit HRP/DAB (Abcam) and HRP-conjugated
polyclonal rabbit antirat immunoglobulin (Dako) diluted
1:200 as secondary antibodies, respectively.
Real-time qPCR analysis
We extracted total RNA from the ankle joints of pGIA or
control mice using the ISOGEN (Wako Pure Chemical
Industries, Tokyo, Japan) extraction method according to
the instructions provided by the manufacturer. The ex-
tracted RNA was reverse-transcribed to complementary
DNA with random primers. We performed real-time
qPCR using a TaqMan gene expression assay (Applied
Biosystems/Thermo Fisher Scientific, Foster City, CA,
USA), and the Padi4 (Mm01341658_m1) and glyceral-
dehyde 3-phosphate dehydrogenase (GAPDH) (NM_
002046) primers. Real-time qPCR was carried out using
an ABI 7500 analyzer (Applied Biosystems). The ex-
pression of GAPDH was used as the control.
Western blot analysis
Serum samples were obtained at days 0, 7, 14, and 28
from mice immunized with pGPI or control, as well as
from patients with RA, SS, SLE, or OA and from HS.
For analysis of citrullinated protein expression, serum
samples were loaded into each well (50 μg for SDS-
PAGE or 100 μg for two-dimensional PAGE [2D-
PAGE]), separated by SDS-PAGE or 2D-PAGE, and
transferred to polyvinylidene difluoride membranes.
The modification buffer was added to the blots before
incubation in a light-proof container at 37 °C for 2.5 h
to modify citrulline residues, as described above. Blots
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were washed with 0.05% Tween 20 in Tris-buffered sa-
line (TBST) and blocked with 5% milk in TBST, then
incubated overnight at 4 °C with AMC antibodies di-
luted 1:3200 in 5% milk in TBST [19]. After a washing
step, the blots were incubated with secondary antibody
HRP-conjugated goat antirabbit IgG (H + L) (Bio-Rad
Laboratories) diluted 1:5000 in 5% milk in TBST for 1
h at room temperature. Densitometric analysis was car-
ried out using an ImageQuant LAS 4000 densitometer
(GE Healthcare Life Sciences, Marlborough, MA, USA).
The band intensity was determined with ImageQuant
TL software (GE Healthcare Life Sciences) and normal-
ized using the value of one sample (pGIA or RA) as 10.
The difference of citrullinated ITIH4 levels from base-
line to 24 weeks after treatment was normalized using
each value at baseline. For analysis of ITIH4 expression,
serum samples were loaded 10 μg/well and Western blot
analysis was performed as described above, using rabbit
antihuman ITIH4 antibodies (Abcam) diluted 1:3000.
Measurement of citrulline content
Sera were obtained at days 0, 7, 14, and 28 from mice
immunized with pGPI or control, and citrulline contents
were measured by using the color development reagent
(COLDER) assay, as described previously [20]. Sera were
diluted 1:100 in COLDER buffer (50 mM NaCl, 10 mM
CaCl2, 2 mM dithiothreitol, and 100 mM Tris, pH 7.4),
and 60 μl of samples were added to the 96-well plates
(Nunc MaxiSorp). Then, 200 μl of COLDER were added
to detect citrullinated proteins. The samples were incu-
bated for 30 minutes at 95 °C. The OD was measured at
570 nm by using a microplate reader and compared with
a standard curve of known citrulline concentrations. Data
were normalized relative to the protein concentration in
each sample.
LC-MS
Sera from pGIA mice, control mice, patients with RA,
and HS were separated by 2D-PAGE, and gels were
stained with GelCode Blue Stain Reagent (Thermo
Fisher Scientific) for Coomassie brilliant blue staining.
Gel slices were incubated overnight with MS-grade
modified trypsin (6.7 ng/μl; Promega, Madison, WI,
USA) at 37 °C. The resultant peptides were analyzed
with the nanoACQUITY ultrahigh-performance LC
(UPLC) system (Waters, Milford, MA, USA). Data
were collected in centroid mode from mass-to-charge
ratios (m/z) 50 to 1990. All analyses were acquired
with an independent reference. BiopharmLynx version 1.2
software (Waters) was used for baseline subtraction and
smoothing, de-isotoping, de novo peptide sequence identi-
fication, and database searches.
Statistical analysis
All data were expressed as mean ± SEM. Differences be-
tween groups were evaluated for statistical significance
using Student’s t test. The Kruskal-Wallis test was used
for evaluation of band intensity among the five subject
groups. P values less than 0.05 were considered signifi-
cant. Statistical analyses were performed using IBM
SPSS Statistics software (IBM, Armonk, NY, USA).
Results
Overexpression of ACPA and citrullinated proteins in
joints and sera in pGIA
First, we investigated the production of ACPA in pGIA.
DBA/1 mice were immunized with pGPI, and we in-
duced symmetrical polyarthritis characterized by severe
swelling of the limb joints (Additional file 1: Figure S1a).
ACPA titers were measured in pGIA sera by ELISA, and
they were significantly higher than those of control mice
(Additional file 1: Figure S1b).
Then, we evaluated the expression of citrullinated pro-
teins in pGIA because high titers of autoantibodies
against citrullinated proteins were detected. Ankle joint
sections were stained with AMC antibodies by IHC.
Citrullinated proteins were detected in joints at day 14
(the peak arthritic phase) and expressed in areas of syn-
ovial hyperplasia in pGIA but not in controls (Fig. 1a).
Citrullinated proteins were not expressed in several
other tissues examined (e.g., lung, spleen, lymph node)
(data not shown). We analyzed the gene expression of
Padi4, which is an enzyme that catalyzes protein citrulli-
nation, in articular tissue samples from pGIA by qPCR.
At day 14, Padi4 levels tended to be higher in the arth-
ritic joints of pGIA mice than in control mice, albeit
insignificantly (Additional file 2: Figure S2a).
In our previous study, PAD4 levels were increased in
sera of patients with RA [21], so we next explored the
expression of citrullinated proteins in sera. Western blot
analysis of serum samples using AMC antibodies identi-
fied citrullinated proteins in pGIA mice but in none of
the control mice (Fig. 1b). Interestingly, the band of
citrullinated protein was detected as a common band at
~ 120 kDa. The band was detected from the prearthritic
phase and with significantly stronger intensity in the
peak arthritic phase, then it decreased in line with the
self-limited arthritis (Fig. 1c). Whereas citrullinated pro-
teins were detected in serum samples (Additional file 3:
Figure S3a, right), they were not detected when Western
blot analysis was performed without modification of
citrulline residues (Additional file 3: Figure S3a, left),
suggesting that the detected band was really specific for
citrulline.
To further confirm the serum levels of citrullinated pro-
teins, we measured citrulline contents in pGIA sera using
the COLDER assay. Serum citrulline content tended to be
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higher in pGIA at day 14 than in the controls (Additional
file 3: Figure S3b). These results suggest that citrullinated
proteins appeared in joints and sera in association with
arthritis in pGIA.
Identification of citrullinated ITIH4 in sera and increase of
ITIH4 in arthritic joints in pGIA
To identify the 120 kDa citrullinated protein in sera, we
analyzed the protein by MS. First, we separated the serum
samples of pGIA by 2D-PAGE and confirmed the spot of
citrullinated proteins at ~ 120 kDa by Western blot
analysis (Fig. 2a, right). Second, the spot in the gels was
sliced after Coomassie brilliant blue staining (Fig. 2a, left),
digested with trypsin, and analyzed by nanoUPLC-MS to
identify the protein. ITIH4 was identified with high
coverage (Table 1), and we examined citrulline modifica-
tions by nanoUPLC-MSE. Citrullination of several sites
containing R438 were identified in ITIH4 from pGIA
(Table 1 and Fig. 2b). Analysis of the samples by MS after
SDS-PAGE (Additional file 4: Figure S4a) also confirmed
the presence of ITIH4 with high coverage, as well as citrul-
lination at R438 in ITIH4 (Additional file 4: Figure S4b).
To further investigate the association between sera
and arthritic joints, we explored the expression of ITIH4
in joints in pGIA. Ankle joint sections were stained with
anti-ITIH4 antibodies by IHC, and liver sections were
stained as positive controls to detect ITIH4 (Additional
file 5: Figure S5a). In naïve mice, ITIH4 was not detected
in joints, but ITIH4 was clearly expressed in inflamed
synovium at day 14 in pGIA (Fig. 2c). Macrophages
Fig. 1 The increase of citrullinated proteins in arthritic joints and sera in peptide glucose-6-phosphate isomerase-induced arthritis (pGIA). a Joint
sections day 0 and day 14 were immunohistochemically stained with anti-modified citrulline (AMC) antibodies in pGIA or control mice. Citrullinated
proteins were detected at day 14 in pGIA mice (indicated by boxed area) but not in control mice. The bottom right image is a magnified view of the
boxed area in the joint image at day 14 of pGIA. Original magnification × 100 and × 400 as marked. The experiments were performed on at least
three different samples with similar results. b Sera from pGIA and control mice at day 14 subjected to Western blot analysis using AMC antibodies.
Citrullinated proteins were detected as a common band at ~ 120 kDa in sera from pGIA mice but not from control mice. Lanes 1–5: control mice; lanes
6–10: pGIA mice. Representative blots are shown at left; data at right are mean ± SEM of band intensity (n = 9). **p < 0.01. c Sera from pGIA mice
subjected to Western blot analysis. Citrullinated proteins appeared from day 7, increased at day 14, and decreased at day 28. Lanes 1–3: day 0; lanes
4–7: day 7, lanes 8–11: day 14, lanes 12–15: day 28. Representative blots are shown at left; data at right are mean ± SEM of band intensity (n = 4).
*p < 0.05, **p < 0.01
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detected by anti-F4/80 antibodies in serial sections showed
colocalization with ITIH4 in some areas (Fig. 2d), suggest-
ing that synovial macrophages may express ITIH4 in joints
of pGIA. Moreover, ITIH4 depositions colocalized with
citrullinated proteins in inflamed synovium in comparative
serial sections (Fig. 2e), suggesting the presence of citrulli-
nated ITIH4 in joints of pGIA. These results indicate the
specific expression of ITIH4 and citrullinated ITIH4 in
arthritic joints in pGIA.
Specific increase of citrullinated ITIH4 in sera of patients
with RA
We also investigated the expression of citrullinated pro-
teins in sera of 60 patients with RA and 30 HS, as well
Fig. 2 Identification of citrullinated inter-alpha-trypsin inhibitor heavy chain 4 (ITIH4) in sera and increase of ITIH4 in arthritic joints in peptide
glucose-6-phosphate isomerase-induced arthritis (pGIA). a Serum samples from pGIA and control mice at day 14 separated by two-dimensional
PAGE, then stained with Coomassie brilliant blue (left) or subjected to Western blot analysis using anti-modified citrulline (AMC) antibodies (right).
Citrullinated proteins were detected at approximately 120 kDa and pH 5.3 in pGIA but not in controls. b The MS spectrum of ITIH4429–438 and
modified peptides bearing the citrullinated arginine (R438) in pGIA. Citrullinated residues were identified by the unmodified b4 ion and the
modified y6, y7, y8, y9, and y10 ion confirmed a mass increase of 1.0D. The experiments depicted in (a) and (b) were performed on at least three
different samples with similar results. c Joint sections at day 0 and day 14 were immunohistochemically stained with anti-ITIH4 antibodies in pGIA or
control mice. ITIH4 were detected at day 14 in pGIA (indicated by boxed area) but not in naïve or control mice at day 14. The image on the fourth
column is a magnified view of the boxed area in the joint image at day 14 of pGIA. Original magnification × 100 and × 400 as marked. d Joint sections
at day 14 were stained with anti-F4/80 antibodies for detection of macrophages (bottom panel) and isotype control antibodies (top panel) in pGIA.
Macrophages colocalized with ITIH4 in some areas in inflamed synovium of pGIA. e Joint sections at day 14 were stained with anti-ITIH4 antibodies
(left bottom panel), AMC antibodies (right bottom panel), and respective isotype control antibodies (top panels) in pGIA. ITIH4 colocalized with
citrullinated proteins in inflamed synovium of pGIA in comparative serial sections. Original magnification × 400
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as in 12 patients with osteoarthritis (OA), 15 patients
with SLE, and 27 patients with SS (disease controls). As
well as in pGIA mice, the 120 kDa band of citrullinated
protein was detected in 82% of patients with RA but in
none of the control groups, except for being faintly de-
tected in 2 patients with SS (7%) and 1 patient with SLE
(7%) (Fig. 3a and Additional file 6: Figure S6a). The
levels of this citrullinated protein were significantly
higher in patients with RA than in controls (Fig. 3b).
We analyzed the 120 kDa citrullinated protein in pa-
tients with RA by 2D-PAGE and MS in the same way as
pGIA mice. Using 2D-PAGE and Western blot analysis,
we first confirmed the spot of citrullinated protein at ~
120 kDa, similar to pGIA (Fig. 3c). Second, MS of this
spot identified ITIH4 with high coverage (Table 2). Ana-
lysis of citrulline modifications identified citrullination of
several sites in ITIH4 from patients with RA. Citrulli-
nated sites varied among individual samples, but the
citrullination of R438 was common among the examined
samples (n = 3) (Table 2 and Fig. 3d).
To confirm whether the 120 kDa citrullinated protein
was ITIH4, we performed Western blot analysis of
serum samples using anti-ITIH4 antibodies. The bands
were detected at 120 kDa by anti-ITIH4 antibodies in
the same position as the bands detected by AMC anti-
bodies (Fig. 3e). In addition, the levels of total ITIH4
were similar in patients with RA and controls, whereas
the levels of citrullinated ITIH4 were specifically in-
creased in patients with RA relative to controls (Fig. 3e).
Using ELISA, we also measured total ITIH4 concentra-
tions in sera from 60 patients with RA and 30 HS who
were the same individuals used in Western blot analysis.
There was no significant difference in total ITIH4 levels
between patients with RA and HS (data not shown).
These results indicate that the levels of citrullinated
ITIH4 rather than total ITIH4 were specifically in-
creased in association with arthritis in sera of patients
with RA.
Correlation between citrullinated ITIH4 levels and disease
activity in patients with RA
Citrullinated ITIH4 was previously identified as one of
various citrullinated proteins in RA synovium [6];
however, its function and association with RA are not
clear. We compared the clinical features of patients with
RA with or without serum citrullinated ITIH4 as con-
firmed by Western blot analysis, using a band intensity
cutoff value of 0.46, representing the mean + 3 SD of
HS. C-reactive protein (CRP) and rheumatoid factor
(RF) levels and Disease Activity Score in 28 joints mea-
sured by CRP (DAS28-CRP) scores were significantly
higher in citrullinated ITIH4-positive than in ITIH4-
negative patients (p = 0.047, p = 0.011, and p = 0.040,
respectively), whereas there was no association between
citrullinated ITIH4 and anti-CCP antibody titer or anti-
CCP antibody-positive rate (Table 3). These results sug-
gest that high levels of citrullinated ITIH4 were associ-
ated with inflammatory markers and disease activity of
patients with RA.
In addition, we analyzed the relationship between
serum citrullinated ITIH4 and RF/ACPA levels in pa-
tients with RA. The levels of citrullinated ITIH4 were
significantly higher in RF+ ACPA+ patients compared
with RF− ACPA+, RF− ACPA− patients (p = 0.011, p = 0.
025, respectively) (Table 4), suggesting that citrullinated
ITIH4 levels were associated with RF levels in patients with
RA. Interestingly, citrullinated ITIH4 were detected in 88%
of RF− ACPA− patients, although those levels were low
(Table 4). It was suggested that positivity of citrullinated
ITIH4 could be a useful marker in seronegative patients
with RA as well.
To further clarify whether serum citrullinated ITIH4
levels were correlated with the disease activity of pa-
tients with RA, we recruited patients who continued
biologic treatment for 24 weeks (infliximab, n = 9; abata-
cept, n = 8) among citrullinated ITIH4-positive patients.
Because treatment with tocilizumab downregulates in-
flammatory markers sometimes irrespective of arthritis
activity, we chose infliximab and abatacept in this ex-
periment. At baseline, the levels of citrullinated ITIH4
were positively correlated with DAS28-CRP, DAS28-
ESR, Simplified Disease Activity Index, and Clinical Dis-
ease Activity Index (Fig. 4a–d). In our comparison of the
differences from baseline to 24 weeks after treatment,
we found that citrullinated ITIH4 levels were decreased
after treatment in responders (Fig. 4e). The difference of
Table 1 Citrullinated inter-alpha-trypsin inhibitor heavy chain 4 was identified in mouse samples by two-dimensional PAGE and
nanoUPLC-MSE
Protein
ID
Protein name Coverage (%) MW (kDa)
Control pGIA
O54882 Inter-alpha-trypsin inhibitor heavy chain 4 55.4 63.9 104.6
Position Peptide sequence Calculated mass Observed mass Arginine
429–438 MALDNGGLA(cit) 1033.50 1033.49 R438
MW Molecular weight, pGIA Peptide glucose-6-phosphate isomerase-induced arthritis
Calculated mass = calculated mass-to-charge ratio of the modified peptides; observed mass = observed mass-to-charge ratio of the modified peptides
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citrullinated ITIH4 levels was significantly correlated
with the difference of DAS28-CRP and DAS28-ESR be-
fore and after treatment (Fig. 4f, g). These results suggest
that serum citrullinated ITIH4 levels were positively cor-
related with disease severity and that citrullinated ITIH4
could be a serum marker reflecting disease activity in
patients with RA.
Autoantigenicity of citrullinated ITIH4
Next, we investigated the autoantigenicity of citrulli-
nated ITIH4. We synthesized a citrulline-containing
ITIH4428–447 peptide (pITIH4) and the corresponding
arginine-containing pITIH4 because R438 was identified
as a dominant citrullination site. We assessed antibody
reactivities against native or citrullinated pITIH4 by
ELISA. On one hand, the levels of anticitrullinated
pITIH4 antibody in patients with RA were significantly
higher than those of HS (Fig. 5a, right). On the other
hand, there was no significant difference in the levels of
antinative pITIH4 antibody between patients with RA
and HS (Fig. 5a, left). When the cutoff value was deter-
mined using sera from HS, 21.7% of RA sera was shown
Fig. 3 Specific increase of citrullinated inter-alpha-trypsin inhibitor heavy chain 4 (ITIH4) in sera in patients with rheumatoid arthritis (RA). a Sera were
separated by SDS-PAGE from patients with RA, healthy subjects (HS), and peptide glucose-6-phosphate isomerase-induced arthritis (pGIA) mice, then
stained with Coomassie brilliant blue (CBB) (left) or subjected to Western blot analysis using anti-modified citrulline (AMC) antibodies (right). Citrullinated
proteins were detected as ~ 120 kDa bands in patients with RA and pGIA mice but in none of the HS. CBB staining is shown to demonstrate loading. Lanes
1–5: HS; lanes 6–11: RA; lane 12: pGIA mice at day 14. b The band intensity of 120 kDa citrullinated protein. Sera from patients with RA (n = 60), HS (n = 30),
patients with osteoarthritis (OA) (n = 12), patients with systemic lupus erythematosus (SLE) (n = 15), and patients with Sjögren’s syndrome (SS) (n = 27)
subjected to Western blot analysis using AMC antibodies. Citrullinated proteins at 120 kDa were specifically increased in patients with RA. Each symbol
represents a single sample. Horizontal bars represent the mean values; vertical bars represent the SEM; and broken line represents the cutoff value.
**p < 0.01, N.S. Not significant. c Serum samples from patients with RA and HS separated by two-dimensional PAGE, then stained with CBB (left) or
subjected to Western blot analysis using AMC antibodies (right). Citrullinated proteins were detected at ~ 120 kDa and pH 5.3 in patients with RA but not
in HS. d The MS spectrum of ITIH4429–438 and modified peptides bearing the citrullinated arginine (R438) in patients with RA. Citrullinated residues identified
by the unmodified b3 and b6 ions and the modified y1, y6, and y8 ions confirmed a mass increase of 1.0 Da. The experiments shown in (c) and (d) were
performed on at least three different samples with similar results. e Serum samples subjected to Western blot analysis using anti-ITIH4 antibodies (Ab) (left)
and AMC antibodies (right). The bands were detected at 120 kDa by anti-ITIH4 antibodies as well as AMC antibodies
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to be reactive with citrullinated pITIH4. The sensitivity
and specificity were 21.7% and 96.7%, respectively. These
results suggest the possibility of an autoimmune reaction
to citrullinated ITIH4 in patients with RA.
Discussion
To our knowledge, this is the first report on high levels of
citrullinated ITIH4 in arthritis. ITIH4 is a heavy-chain
protein, and ITIHs form inter-alpha-trypsin inhibitors
(ITIs) by binding to a common light chain [22, 23]. Mem-
bers of the ITI family are recruited to extravascular sites,
where ITIHs are converted to hyaluronan (HA), to form
serum-derived HA-associated protein (SHAP)-HA com-
plexes in HA-rich tissues such as synovial fluid [22, 23].
Researchers in previous studies reported high levels of
SHAP-HA complexes in RA serum and synovial fluid,
suggesting their association with inflammation through
the regulation of adhesion of infiltrating leukocytes [24].
In particular, ITIH4 was identified as one of various
citrullinated proteins in RA synovium [6]. In addition, hu-
man ITIHs are reported to inhibit the complement sys-
tem, suggesting a link to the immunocomplex cascades
[25]. More recently, high serum levels of anticitrullinated
ITIH3 antibodies were found in patients with RA [26].
In the present study, we show that citrullinated ITIH4
was recognized with high specificity in patients with RA
as compared with patients with other autoimmune and
arthritic diseases or in HS, indicating a potential role for
citrullinated ITIH4 in RA pathogenesis. Additionally, in
the investigation of autoantigenicity of citrullinated
ITIH4, higher levels of anticitrullinated pITIH4 antibody
were observed in patients with RA than in HS, whereas
there was no significant difference in the levels of antina-
tive pITIH4 antibody. These results suggest that citrulli-
nated ITIH4 may be one of the candidate targets of ACPA
and may be involved in the inflammatory response by
forming immune complexes, which play an important role
in the pathophysiology of RA [27]. ITIH4 has been
Table 3 Comparison of clinical features of patients with rheumatoid arthritis with or without serum citrullinated inter-alpha-trypsin
inhibitor heavy chain 4
Total Citrullinated ITIH4 p Value
+ –
No. of patients (%) 60 49 (82%) 11 (18%)
Age, years 52.2 ± 1.9 51.3 ± 2.2 55.9 ± 3.9 0.355
Females, n (%) 48 (80%) 38 (78%) 10 (91%) 0.317
DAS28-CRP score 3.9 ± 0.2 4.1 ± 0.2 3.3 ± 0.4 0.040
CRP, mg/dl 2.18 ± 0.30 2.46 ± 0.34 0.93 ± 0.56 0.047
Anti-CCP antibodies, U/ml 131.6 ± 21.6 138.9 ± 24.6 93.4 ± 39.0 0.462
Positive, n (%) 46 (82%) 39 (83%) 7 (78%) 0.709
RF, U/ml 210.6 ± 46.1 242.3 ± 55.0 69.5 ± 35.5 0.011
MMP-3, ng/ml 198.5 ± 21.8 214.7 ± 25.7 127.9 ± 20.1 0.122
PSL use, n (%, mean dose in mg/day) 51 (85%, 6.9) 41 (84%, 7.1) 10 (91%, 6.4) 0.544
MTX use, n (%, mean dose in mg/week) 40 (67%, 10.1) 31 (63%, 10.1) 10 (91%, 10.0) 0.075
Abbreviations: ITIH4 Inter-alpha-trypsin inhibitor heavy chain 4, DAS28-CRP Disease Activity Score in 28 joints as measured by C-reactive protein, CRP C-reactive
protein, CCP Cyclic citrullinated peptide, RF Rheumatoid factor, MMP-3 Matrix metalloproteinase 3, PSL Prednisolone, MTX Methotrexate
Values are mean ± SEM. The cutoff value for positive citrullinated ITIH4 was band intensity of 0.46, representing the mean + 3 SD of healthy subjects
Table 2 Citrullinated inter-alpha-trypsin inhibitor heavy chain 4 was identified in human samples by two-dimensional PAGE and
nanoUPLC-MSE
Protein ID Protein name Coverage (%) MW (kDa)
HS RA
B7Z545 Inter-alpha-trypsin inhibitor heavy chain 4 40.0 – 99.7
B2RMS9 Inter-alpha-trypsin inhibitor heavy chain 4
(inter-alpha globulin inhibitor H4)
– 42.3 103.3
Position Peptide sequence Calculated mass Observed mass Arginine
429–438 LALDNGGLA(cit) 999.55 999.53 R438
Abbreviations: HS Healthy subjects, MW Molecular weight, RA Rheumatoid arthritis
Calculated mass = calculated mass-to-charge ratio of the modified peptides; observed mass = observed mass-to-charge ratio of the modified peptides
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reported to have an anti-inflammatory role, such as inhib-
ition of the phagocytosis of polymorphonuclear cells [28].
Regarding the pathogenetic role of citrullinated ITIH4 in
RA, another possibility is that citrullination of ITIH4
might suppress the anti-inflammatory effect of ITIH4 in
situ, because the biologic activity of many proteins will be
affected by their citrullination. Further studies are needed
to evaluate the precise role of citrullinated ITIH4 in RA
pathogenesis.
Which cells express ITIH4, and how and where is ITIH4
citrullinated? In this study, ITIH4 and macrophages colo-
calized in some areas in inflamed synovium of pGIA. These
results suggest that synovial macrophages may express
ITIH4 in pGIA, but there is a limitation of comparing
serial sections by IHC. In addition, ITIH4 was also found
in synovial or cartilage surface layers in pGIA, suggesting
the presence of ITIH4 in the synovial fluid. It is possible
that circulating ITIH4 was recruited into synovial fluid,
because the ITI family was synthesized by hepatocytes and
recruited to extravascular sites such as the synovial fluid
[22, 23], and ITIH4 and citrullinated ITIH4 were also de-
tected in RA synovial fluid (our preliminary observations),
supporting the possibility of this scenario. In previous
reports, peptidyl arginine deiminase 2 (PAD2) and PAD4
enzymes were increased in RA synovium or synovial fluid,
and they contributed to protein citrullination in arthritic
joints [5, 29, 30]. In this study, we show higher levels of
Padi4 in the arthritic joints of pGIA, as well as the
Fig. 4 Relationship between citrullinated inter-alpha-trypsin inhibitor heavy chain 4 (ITIH4) levels and disease activity in patients with rheumatoid arthritis
(RA). a–d Correlation between citrullinated ITIH4 levels and disease activity score in 28 joints (DAS28) as measured by C-reactive protein (DAS28-CRP) (a),
DAS28-ESR (b), Simplified Disease Activity Index (SDAI) (c), and Clinical Disease Activity Index (CDAI) (d) at baseline in patients with RA (n = 17). e Sera
from patients with RA at baseline or 24 weeks after biologic treatment subjected to Western blot analysis using anti-modified citrulline antibodies.
Citrullinated ITIH4 levels were decreased after effective treatment. Lanes 1–8: Each individual, lanes 1and 2: abatacept treatment samples, lanes 3–8:
infliximab treatment samples, Lanes marked (−): baseline samples; lanes marked (+):posttreatment samples. f and g Correlation between the difference of
citrullinated ITIH4 levels (expressed as the normalized difference of band intensity) and the difference of (f) DAS28-CRP or (g) DAS28-ESR before and after
treatment (n = 17). r is the correlation coefficient
Table 4 Relationship between serum citrullinated inter-alpha-trypsin inhibitor heavy chain 4 and rheumatoid factor/anticitrullinated
protein antibodies levels in patients with rheumatoid arthritis
RF+ ACPA+ RF+ ACPA− RF− ACPA+ RF− ACPA−
No. of patients (%) 42 (75%) 2 (4%) 4 (7%) 8 (14%)
Cit-ITIH4 level 2.2 ± 0.5 1.3 ± 0.9 0.6 ± 0.3 0.9 ± 0.3
Cit-ITIH4-positive, n (%) 38 (91%) 1 (50%) 1 (25%) 7 (88%)
Abbreviations: Cit-ITIH4 Citrullinated inter-alpha-trypsin inhibitor heavy chain 4, RF Rheumatoid factor, ACPA Anticitrullinated protein antibody
Cit-ITIH4 levels are mean ± SEM of band intensity
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expression of ITIH4 and citrullinated ITIH4 in inflamed
synovium of pGIA. Taking these findings together, we
speculate that citrullination of ITIH4 was induced by aber-
rant PAD activity in arthritic joints and leaked into the
blood circulation.
In this study, on one hand, serum citrullinated ITIH4
levels varied in relation to the clinical findings of pGIA,
increasing at day 14 then falling at day 28. On the other
hand, ACPA titers were significantly higher after day
21, despite the gradual resolution of arthritis. Further-
more, our preliminary studies showed that treatment
with Cl-amidine (PAD inhibitor) resulted in suppres-
sion of arthritis coupled with a significant decrease in
serum citrullinated ITIH4 levels, although there was no
significant decrease in ACPA titers in pGIA. In patients
with RA, the levels of CRP, RF, and DAS28-CRP were
significantly higher in patients with RA positive for
serum citrullinated ITIH4. In addition, basal serum
citrullinated ITIH4 levels were significantly correlated
with disease activity markers in patients with active RA
and decreased after effective treatment in correlation
with the disease activity. These results suggest that
citrullinated ITIH4, not ACPA, seems to fluctuate in
parallel with the severity of arthritis and could be a
disease-specific biomarker representing the disease ac-
tivity of patients with RA.
We observed that there were several citrullinated
sites in ITIH4, and those sites were not identical be-
tween pGIA and patients with RA, and they were
different between individuals. However, the R438 site
was commonly citrullinated in our analyzed samples.
Thus, this position is considered as a dominant citrul-
linated site. We show that the antibody reactivities
against ITIH4428–447 peptides containing citrullinated
R438 were significantly higher in patients with RA
than in HS, whereas there was no significant difference
in the reactivities against native ITIH4428–447 peptides
containing arginine. Furthermore, the levels of antici-
trullinated pITIH4 antibody tended to be higher than
those of native pITIH4 in patients with RA, although
there was no significant difference. There is a possibil-
ity that this citrullinated epitope in ITIH4 may be one
of the targets of the immune system in RA. Nonethe-
less, the reactivities against the synthesized linear
citrullinated peptides do not necessarily completely
reflect the reactivities against the corresponding citrul-
linated proteins in vivo, and there is also a possibility
of antibodies cross-reacting. It is necessary to verify in
future studies the antibody reactivities against whole
citrullinated ITIH4 or circulating citrullinated epitopes
at several other sites.
Conclusions
We show in the present study the specific expression
of citrullinated proteins in joints and sera in pGIA.
Notably, we demonstrate that the increase of specific
citrullinated protein in sera as citrullinated ITIH4
fluctuated with the arthritis score. Also, in patients
with RA, citrullinated ITIH4 levels were specifically in-
creased in sera and significantly correlated with disease
activity. Therefore, citrullinated ITIH4 could be a novel
biomarker to distinguish RA from other rheumatic
diseases and for assessing disease activity in patients
with RA.
Additional files
Additional file 1: Figure S1. DBA/1 mice were immunized with pGPI.
(a) The clinical score (mean ± SEM) of pGIA (n = 11). (b) Sera were
obtained once per week between days 0 and 28 from pGIA and control
mice. The titers of anti-CCP antibodies were analyzed by ELISA (n = 12–18).
Each symbol represents a single mouse, and the horizontal and vertical bars
represent the mean and SEM values, respectively. *p < 0.05, **p < 0.01.
(TIFF 120 kb)
Additional file 2: Figure S2. (a) Padi4 gene expression levels in articular
tissue samples from pGIA and control mice, analyzed by qPCR (n = 6).
Data are mean ± SEM. (TIFF 97 kb)
Additional file 3: Figure S3. (a) Serum samples obtained at day 14
from pGIA mice. Western blot analysis was performed without
modification of citrulline residues, but no bands of citrullinated proteins
were detected (left). Western blot analysis performed with modification of
citrulline residues allowed detection of the bands (right). G1–G3 Samples
of different mice. (b) Serum of mice immunized with pGPI or CFA control
were subjected to the color development reagent assay to measure
citrulline content (n = 6). Each symbol represents a single mouse. The
horizontal and vertical bars represent the mean and SEM values for the
group, respectively. (TIFF 149 kb)
Additional file 4: Figure S4. (a) Sera of pGIA and control mice
obtained at day 14 were separated by SDS-PAGE and stained with
Coomassie brilliant blue (left) or subjected to Western blot analysis using
AMC antibodies (right). Citrullinated proteins were detected at ~ 120 kDa
Fig. 5 Autoantigenicity of citrullinated peptide 428–447 inter-alpha-
trypsin inhibitor heavy chain 4 (pITIH4) in patients with rheumatoid
arthritis (RA). a Antibody reactivities against native or citrullinated
pITIH4 were analyzed in patients with RA (n = 60) and healthy sub-
jects (HS) (n = 30) by enzyme-linked immunosorbent assay. Each
symbol represents a single sample. Bars show the mean ± SEM;
broken line represents the cutoff value. **p < 0.01. N.S. Not significant
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in pGIA mice but not in the control mice. G1, 2: pGIA; C1, 2: control mice.
(b) The MS spectrum of ITIH4429–438 and modified peptides bearing the
citrullinated arginine (R438) in pGIA. Citrullinated residues were identified
by the modified y6, y7, and y8 ion confirmed a mass increase of 1.0 Da.
(TIFF 217 kb)
Additional file 5: Figure S5. (a) Liver tissue sections from naïve mice
were immunohistochemically stained with anti-ITIH4 antibodies as a posi-
tive control to detect ITIH4. (TIFF 263 kb)
Additional file 6: Figure S6. (a) Sera from patients with RA, HS, patients
with OA, patients with SLE, and patients with SS was subjected to Western
blot analysis using AMC antibodies. Citrullinated proteins were specifically
detected as an ~ 120 kDa band in patients with RA. (TIFF 238 kb)
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